Navigation Links
Anesiva Appoints Daniel Janney to Board of Directors
Date:2/8/2008

SOUTH SAN FRANCISCO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today the appointment of Daniel S. Janney to the company's board of directors. Mr. Janney previously served on Anesiva's board from November 2000 through December 2005, when he transitioned off the board following the merger of Anesiva and AlgoRx Pharmaceuticals.

"Dan was an excellent contributor to the Anesiva board of directors, and we are very pleased to welcome him back, especially at such an important time in the company's evolution as we prepare to commercialize our first product, Zingo(TM), in the second quarter of 2008," stated John P. McLaughlin, chief executive officer of Anesiva. "We are fortunate to have a strong board of directors at Anesiva with a broad mix of experiences including individuals who are experts in their fields of pain management and biopharma product marketing. Dan serves on the boards of multiple bioscience companies, and we look forward to drawing upon the extensive leadership experience he brings to the table."

Since 1996, Daniel S. Janney has been a managing director of Alta Partners, a venture capital firm investing in information technologies and life sciences companies and was a co-founder of the Alta BioPharma effort. In addition to Anesiva, he currently serves on the board of directors of a number of companies, including Acureon Pharmaceuticals, Alba Therapeutics, ChemGenex Pharmaceuticals, Kemia, Phenomix Corporation and ViroBay. He has been directly involved in the funding and development of over 25 life sciences companies. Previously, Mr. Janney was a senior investment banker at Montgomery Securities focusing on life science companies, prior to which he was at Bankers Trust Company in its leveraged buyout/private equity group. Mr. Janney received a B.A. in History from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Anesiva Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
2. Anesiva Announces Completion of Common Stock Offering
3. Anesiva Raises $45 Million in Common Stock Offering
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
7. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... announces the commercial launch of flexible packaging for their exceptionally efficient human ... bag system extends RoosterBio’s portfolio of bioprocess media products engineered to radically ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):